Have you had Parkinson’s disease for at least 5 years?
If so, you may be eligible for a biomarkers study that will help us learn more about Parkinson’s disease.

STUDY DETAILS:

- **What is the goal of this study?** To identify one or more biomarkers of Parkinson’s disease. The discovery of a biomarker is critical to the development of new and improved treatments for Parkinson’s disease, particularly treatments that could slow or stop the progression of the disease, something not currently available. This study aims to identify new biomarker candidates.

- **What is a biomarker?** A biomarker is a substance or characteristic in our bodies that is associated with the presence of disease, or that changes over time in a way that can be linked to the progression of disease.

- **What is an observational study?** An observational study means that study participants will undergo numerous tests and assessments of bodily processes related to Parkinson’s disease, but will not receive an experimental drug or treatment.

- **Who qualifies for the study?** Individuals who are between 55 and 93 years of age are eligible to participate. Individuals must have had PD for at least 5 years and for no more than 18 years. This study also seeks control volunteers who do not have PD.

- **What is involved if I participate?** Volunteers for this study will visit the site twice in a two week period. At the first visit, individuals will have several clinical assessments and take written surveys. The second visit will include a smaller number of clinical tests, as well as sample collection, including a blood draw and a lumbar puncture.

- **Will I be compensated for participation?** Participants will receive study procedures at no charge, will receive a stipend to cover travel expenses, and will also receive education and support during the study.

If you are interested in participating or want to learn more, please contact Ray James, BS, RN, 617-638-7745
Boston University Medical Center

Sponsored by The Michael J. Fox Foundation for Parkinson’s Research
with funding provided in part by the National Institute of Neurological Disorders and Stroke.